A Study of Mirikizumab in Healthy Chinese Participants

NCT04137380 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Mirikizumab - IV
DRUG: Mirikizumab - SC
DRUG: Placebo - IV
DRUG: Placebo - SC

Sponsor

Eli Lilly and Company